Clinical Correlation of Cadherin-17 (CA17 Aka CDH17) Marker with Advanced Tumor Stages and Poor Prognosis of Cholangiocarcinoma in a Retrospective Cohort of 180 Patients.
Zheng Bohao,Shen Sheng,Tony K. Wong,Gong Zi-Jun,Sun Wentao,Ni Xiaojian,Wang Jiwen,Hu Mei-Yu,Liu Han,Ni Xiaoling,Liu Houbao,Moon Ching Luk,Suo Tao
DOI: https://doi.org/10.1200/jco.2021.39.3_suppl.344
IF: 45.3
2021-01-01
Journal of Clinical Oncology
Abstract:344 Background: Aberrant expression of cadherin-17 (CA17, aka CDH17) cancer marker is often observed in major gastrointestinal (GI) cancers. In this retrospective study, we examined the CA17 tissue expression and analyzed its clinical significance in cholangiocarcinoma (CCA). Methods: A total of 180 patients with detailed demographic and clinical data were enrolled in this study and randomly divided into a training cohort (N = 120) and a validation cohort (N = 60). Biopsy samples (tumor and adjacent normal tissue) collected for tissue microarray were examined by immunohistochemistry using a mouse anti-CA17 monoclonal antibody (Clone 7C5). Image pro plus was applied to score the staining intensity and expression level of CA17 marker. Kaplan-Meier analysis, Cox's proportional hazards regression, and nomogram were applied to evaluate the prognostic significance of CA17. Results: CA17 cancer biomarker over-expression was significantly observed in CCA compared to their non-tumor counterparts (P < 0.001), and positively correlated with aggressive tumor phenotypes, like larger tumor size (P = 0.004), lymph node metastasis (P < 0.001), and advanced TNM stage (P < 0.001). Meanwhile, patients with high expression of CA17 correlated with worse postoperative overall survival (OS)(P = 0.002) and recurrence-free survival (P = 0.03). Besides, multivariate analysis identified that CA17 expression was an independent prognostic factor for cholangiocarcinoma patients (Training cohort: HR:1.716, 95% CI:1.116-2.638; P = 0.014; Validation cohort: HR: 1.811, 95%CI:1.028-3.892; P = 0.035), which indicated that the CA17 is much more efficient than serum CA19-9 (Training cohort: HR: 1.000, 95%CI: 1.000-1.001; P = 0.006; Validation cohort: HR: 1.000,95%CI:1.000-1.001; P = 0.013) in predicting the OS of CCA patients. Notably, the nomogram integrating CA17 expression had a better prognostic performance as compared with current TNM staging systems. Conclusions: CA17 cancer biomarker was aberrantly expressed in CCA tumor tissues, and its high expression level positively correlated with aggressive tumor phenotypes. Furthermore, CA17 was an independent adverse prognostic factor for CCA patients’ survival, which may serve as a potential drug target for CCA patients.